ENTXEntera Bio Ltd.

Nasdaq enterabio.com


$ 1.63 $ 0.06 (3.56 %)    

Friday, 16-Aug-2024 15:57:45 EDT
QQQ $ 475.24 $ 0.61 (0.13 %)
DIA $ 406.80 $ 0.86 (0.21 %)
SPY $ 554.24 $ 1.24 (0.22 %)
TLT $ 97.41 $ 0.34 (0.35 %)
GLD $ 231.90 $ 5.08 (2.24 %)
$ 1.63
$ 1.61 x 100
-- x --
-- - --
$ 0.52 - $ 3.35
23,815
na
60.46M
$ 1.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-08-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-05-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-08-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

 entera-bio-q2-eps-006-inline-sales-5700k

Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 62....

 entera-to-present-eb613-once-daily-pth1-34-tablet-treatment-dedicated-to-post-menopausal-women-with-high-risk-osteoporosis-abstract-at-the-asbmr-2024-annual-meeting-key-sabre-update-also-expected

Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of orally delivered pept...

 hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

 entera-bio-presents-phase-1-clinical-data-of-oral-pth1-34-peptide-candidate-eb612-for-patients-with-hypoparathyroidism-at-endo-2024

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered pept...

 hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

 hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

 entera-bio-q1-eps-005-beats-006-estimate

Entera Bio (NASDAQ: ENTX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) b...

 entera-bio-announces-publication-of-oral-pth1-34-peptide-tablets-eb613-phase-2-trial-data-i1n-the-journal-of-bone-and-mineral-research

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered pept...

 hc-wainwright--co-maintains-buy-on-entera-bio-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price tar...

 entera-bio-announces-key-regulatory-milestone-for-oral-pth1-34-peptide-eb613-phase-3-program-fda-ruling-on-qualifying-bmd-as-a-surrogate-endpoint-for-osteoporosis-drugs-is-expected-within-10-months

Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of orally delivered pept...

 entera-bio-fy23-eps-031-vs-041-yoy-as-of-december-31-2023-entera-had-cash-and-cash-equivalents-of-110m

Financial Results for the year Ended December 31, 2023As of December 31, 2023, Entera had cash and cash equivalents of $11.0 mi...

 entera-bio-regains-compliance-with-nasdaq-minimum-bid-price-requirement

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered pept...

 entera-bio-and-3-other-stocks-under-1-insiders-are-buying

The Dow Jones index closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or...

 hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

 interim-results-from-ongoing-clinical-study-confirm-eb613-optimized-profile-for-osteoporosis-treatment-and-potential-for-enteras-next-generation-oral-peptide-platform

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered pept...

 entera-bio-reports-rapid-pharmacodynamic-response-and-consistent-pharmacokinetic-data-for-its-first-in-class-oral-pth1-34-mini-tablets-at-the-asbmr-2023-annual-meeting

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered pept...

 hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION